Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 12/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745167 | 0.82 | TGFBR1 (0.40) | TGFBR1CYP1A2CYP2C9ALDH1A1ADORA2A | |
| SCHEMBL10238918 | 0.75 | CYP1A2 (0.56) | TGFBR1CYP1A2CYP2C9ALDH1A1POLB | |
| SCHEMBL4251225 | 0.73 | TGFBR1 (0.62) | TGFBR1ALDH1A1 | |
| SCHEMBL4260578 | 0.73 | PIK3CA (0.46) | TGFBR1 | |
| SCHEMBL4253849 | 0.72 | CHEK1 (0.50) | — | |
| SCHEMBL4252029 | 0.72 | TGFBR1 (0.39) | TGFBR1 | |
| SCHEMBL17754846 | 0.72 | TGFBR1 (0.43) | TGFBR1CYP1A2CYP2C9POLBADORA2A | |
| SCHEMBL16404632 | 0.72 | POLB (0.56) | TGFBR1CYP1A2CYP2C9ALDH1A1POLB | |
| SCHEMBL12998303 | 0.72 | PIK3CA (0.47) | TGFBR1CYP1A2CYP2C9ADORA2A | |
| SCHEMBL16368027 | 0.72 | TGFBR1 (0.43) | TGFBR1CYP1A2CYP2C9ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PI4KA, PIP4K2A | TGFBR1 444/4885CYP1A2 2574/4885CYP2C9 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.